Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland

Jamie Bainbridge, Stuart Mealing, Charlotte Graham, Mathias Jenal, Nicolas von Dombrowski, Amy Dymond · 2026

Read Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland by Jamie Bainbridge, Stuart Mealing, Charlotte Graham, Mathias Jenal, Nicolas von Dombrowski, Amy Dymond (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13687221.txt.

Description

A peer-reviewed research article from Europe PMC (2026). BackgroundRSVpreF is a vaccine that immunises against respiratory syncytial virus (RSV), a seasonal respiratory virus, that can lead to lower respiratory tract infections. In Switzerland, RSVpreF is indicated for the passive protection of infants against RSV following maternal immunisation.ObjectiveThe Swiss Federal Office of Public Health commissioned a health technology assessment (HTA) of RSVpreF for maternal vaccination, evaluating the clinical and cost effectiveness of the vaccine compared with nirsevimab (administered directly to newborns and infants) or no RSV prophylaxis.

Catalog record

CREATORJamie Bainbridge, Stuart Mealing, Charlotte Graham, Mathias Jenal, Nicolas von Dombrowski, Amy Dymond
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13687221

Browse the full library · About the Tower of Babel